Network medicine analysis of COPD multimorbidities

Respiratory Research

Laura I Furlong²  Ferran Sanz²  Joaquim Gea¹  Alvar Agustí⁴  Borja Cosío⁵  Josep Roca⁴  Janet Piñero²  Rosa Faner³  Antoni Ferrer¹  Solène Grosdidier² 

[1] Servei de Pneumologia, IMIM (Hospital del Mar Research Institute), Barcelona, DCEXS, Universitat Pompeu Fabra, CIBERES, Barcelona, Spain;Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Barcelona, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain;FISIB, CIBERES, Palma de Mallorca, Spain;Thorax Institute, Hospital Clínic, IDIBAPS, Universitat Barcelona, Barcelona, Spain;Hospital Universitari Son Espases-IdISPa, Ciberes, Palma de Mallorca, Spain

关键词: Tobacco chemicals;    COPD;    Multimorbidity;    Comorbidity;    Network medicine;    Systems biology;    Diseasome;   

Others  :  1137264
DOI  :  10.1186/s12931-014-0111-4

 received in 2014-05-22, accepted in 2014-08-12,  发布年份 2014

【 摘 要 】

Background

Patients with chronic obstructive pulmonary disease (COPD) often suffer concomitant disorders that worsen significantly their health status and vital prognosis. The pathogenic mechanisms underlying COPD multimorbidities are not completely understood, thus the exploration of potential molecular and biological linkages between COPD and their associated diseases is of great interest.

Methods

We developed a novel, unbiased, integrative network medicine approach for the analysis of the diseasome, interactome, the biological pathways and tobacco smoke exposome, which has been applied to the study of 16 prevalent COPD multimorbidities identified by clinical experts.

Results

Our analyses indicate that all COPD multimorbidities studied here are related at the molecular and biological level, sharing genes, proteins and biological pathways. By inspecting the connections of COPD with their associated diseases in more detail, we identified known biological pathways involved in COPD, such as inflammation, endothelial dysfunction or apoptosis, serving as a proof of concept of the methodology. More interestingly, we found previously overlooked biological pathways that might contribute to explain COPD multimorbidities, such as hemostasis in COPD multimorbidities other than cardiovascular disorders, and cell cycle pathway in the association of COPD with depression. Moreover, we also observed similarities between COPD multimorbidities at the pathway level, suggesting common biological mechanisms for different COPD multimorbidities. Finally, chemicals contained in the tobacco smoke target an average of 69% of the identified proteins participating in COPD multimorbidities.

Conclusions

The network medicine approach presented here allowed the identification of plausible molecular links between COPD and comorbid diseases, and showed that many of them are targets of the tobacco exposome, proposing new areas of research for understanding the molecular underpinning of COPD multimorbidities.

【 授权许可】

   
2014 Grosdidier et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Mannino DM, Kiriz VA: Changing the burden of COPD mortality. Int J Chron Obstruct Pulmon Dis 2006, 1:219-233.
• [2]Agustí A, Vestbo J: Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 184:507-513.
• [3]Agusti A, Sobradillo P, Celli B: Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med 2011, 183:1129-1137.
• [4]Fabbri LM, Beghé B, Agustí A: COPD and the solar system: introducing the chronic obstructive pulmonary disease comorbidome. Am J Respir Crit Care Med 2012, 186:117-119.
• [5]Dm M, Thorn D, Swensen A, Holguin F: Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008, 32:962-969.
• [6]Barnes PJ: Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med 2010, 7:e1000220.
• [7]Park J, Lee DS, Christakis NA, Barabási AL: The impact of cellular networks on disease comorbidity. Mol Syst Biol 2009, 5:262.
• [8]Lee DS, Park J, Kay KA, Christakis NA, Oltvai ZN, Barabási AL: The implications of human metabolic network topology for disease comorbidity. Proc Natl Acad Sci USA 2008, 105:9880-9885.
• [9]Barabási AL, Gulbahce N, Loscalzo J: Network medicine: a network-based approach to human disease. Nat Rev Genet 2011, 12:56-68.
• [10]Divo M, Cote C, De Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, Celli B: Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:155-161.
• [11]Furlong LI: Human diseases through the lens of network biology. Trends Genet 2013, 29:150-159.
• [12]Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G: Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010, 80:112-119.
• [13]Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE: Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010, 65:956-962.
• [14]Schnell K, Weiss CO, Lee T, Krishnan JA, Leff B, Wolff JL, Boyd C: The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008. BMC Pulm Med 2012, 12:26. BioMed Central Full Text
• [15]Bodenreider O: The unified medical language system (UMLS): integrating biomedical terminology. Nucleic Acids Res 2004, 32:D267-D270.
• [16]Bauer-Mehren A, Rautschka M, Sanz F, Furlong LI: DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks. Bioinformatics 2010, 26:2924-2926.
• [17]Cerami EG, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N, Schultz N, Bader GD, Sander C: Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res 2011, 39:D685-D690.
• [18]Schaefer MH, Fontaine JF, Vinayagam A, Porras P, Wanker EE, Andrade-Navarro MA: HIPPIE: Integrating protein interaction networks with experiment based quality scores. PLoS One 2012, 7:e31826.
• [19]Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, Caudy M, Garapati P, Gopinath G, Jassal B, Jupe S, Kalatskaya I, Mahajan S, May B, Ndegwa N, Schmidt E, Shamovsky V, Yung C, Birney E, Hermjakob H, D'Eustachio P, Stein L: Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res 2011, 39:D691-D697.
• [20]Yu G: ReactomePA: Reactome Pathway Analysis R package version 2.15.2. 2012.
• [21]Perez-Llamas C, Lopez-Bigas N: Gitools: analysis and visualisation of genomic data using interactive heat-maps. PLoS One 2011, 6:e19541.
• [22]Rustemeier K, Stabbert R, Haussmann HJ, Roemer E, Carmines EL: Evaluation of the potential effects of ingredients added to cigarettes. Part 2: chemical composition of mainstream smoke. Food Chem Toxicol 2002, 40:93-104.
• [23]Hoffmann D, Hoffmann I: Tobacco smoke components. Beiträge zur Tabakforschung Int 1998, 18:49-52.
• [24]Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33:1165-1185.
• [25]Corsonello A, Incalzi RA, Pistelli R, Pedone C, Bustacchini S, Lattanzio F: Comorbidities of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2011, 17(Suppl 1):S21-S28.
• [26]Thomsen M, Dahl M, Tybjaerg-Hansen A, Nordestgaard BG: β2 -adrenergic receptor Thr164IIe polymorphism, blood pressure and ischaemic heart disease in 66 750 individuals. J Intern Med 2012, 271:305-314.
• [27]Prior SJ, Goldberg AP, Ryan AS: ADRB2 haplotype is associated with glucose tolerance and insulin sensitivity in obese postmenopausal women. Obesity (Silver Spring) 2011, 19:396-401.
• [28]Lacey RJ, Cable HC, James RF, London NJ, Scarpello JH, Morgan NG: Concentration-dependent effects of adrenaline on the profile of insulin secretion from isolated human islets of Langerhans. J Endocrinol 1993, 138:555-563.
• [29]Hersh CP: Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities. Pharmacogenomics 2010, 11:237-247.
• [30]Papatheodorou A, Makrythanasis P, Kaliakatsos M, Dimakou A, Orfanidou D, Roussos C, Kanavakis E, Tzetis M: Development of novel microarray methodology for the study of mutations in the SERPINA1 and ADRB2 genes–their association with Obstructive Pulmonary Disease and Disseminated Bronchiectasis in Greek patients. Clin Biochem. 2010, 43:43-50.
• [31]Thomsen M, Nordestgaard BG, Sethi AA, Tybjærg-Hansen A, Dahl M: β2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies. Eur Respir J 2012, 39:558-566.
• [32]Zee RY, Cook NR, Reynolds R, Cheng S, Ridker PM: Haplotype analysis of the beta2 adrenergic receptor gene and risk of myocardial infarction in humans. Genetics 2005, 169:1583-1587.
• [33]Mattingly CJ, Rosenstein MC, Davis AP, Colby GT, Forrest JN, Boyer JL: The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks. Toxicol Sci 2006, 92:587-595.
• [34]Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, Zielinski J: Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
• [35]DeMeo DL, Carey VJ, Chapman HA, Reilly JJ, Ginns LC, Speizer FE, Weiss ST, Silverman EK: Familial aggregation of FEF(25–75) and FEF(25–75)/FVC in families with severe, early onset COPD. Thorax 2004, 59:396-400.
• [36]Pechnick RN, Zonis S, Wawrowsky K, Pourmorady J, Chesnokova V: p21Cip1 restricts neuronal proliferation in the subgranular zone of the dentate gyrus of the hippocampus. Proc Natl Acad Sci U S A 2008, 105:1358-1363.
• [37]Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA: Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 2011, 476:458-461.
• [38]Yoshida T, Tuder RM: Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev 2007, 87:1047-1082.
• [39]Bauer-Mehren A, Furlong LI, Sanz F: Pathway databases and tools for their exploitation: benefits, current limitations and challenges. Mol Syst Biol 2009, 5:290.